Gilead Sciences, inc. Stock's Green Light Sparks Offensive
Gilead Sciences got the FDA go-ahead last week for its next generation Harvoni, a hepatitis C drug that offers what amounts to a functional cure for most hepatitis C patients. The approval isn't a surprise. Industry watchers and Gilead competitors were widely expecting a green light based on impressive late stage trial data showing that as many as 99% of patients taking Harvoni were effectively cured of the disease.
Those results sparked doctors to begin warehousing patients for treatment during the third quarter; but doctors weren't the only ones watching regulators closely last week. Fears tied to Harvoni's pricing likely had executives at healthcare insurers like UnitedHealth Group on the edge of their seats, too.
Harvoni isn't Gilead's first breakthrough drug for treating hepatitis C; that moniker belongs to Sovaldi. Gilead paid more than $11 billion to buy Pharmasset in 2012 to acquire Sovaldi. When FDA regulators approved Sovaldi last December, Gilead shocked the industry by slapping an $84,000 price tag on a 12-week treatment course.
Sovaldi's price was a significant jump from Vertex Pharmaceuticals' previous blockbuster hepatitis C drug Incivek, which cost about $50,000. It also marked a massive increase from the $20,000 payers were coughing up for a side-effect laden treatment course of ribavirin and peg interferon just a few years earlier.
Sovaldi's price prompted specialty drug distributor Express Scripts to yell "foul" and led to a wave of Congressional inquiries to investigate whether Gilead's pricing was exorbitant and ostensibly cold-hearted. The attention made Sovaldi the most controversial, revolutionary medicine approved in recent history. Through it all, however, Gilead remained unfazed and unwilling to budge on Sovaldi's cost.
Instead, Gilead rolled out a slate of evidence suggesting that Sovaldi's price was not only in line with the cost of treating patients with a combination of Incivek, ribavirin, and peg interferon, but was also a bargain when compared to the nosebleed spending associated with liver transplants for the sickest of hepatitis C patients. As a result, Sovaldi became the fastest drug ever launched to reach the $1 billion blockbuster sales mark, leading to Gilead's Sovaldi sales totaling more than $5 billion through the first six months of this year.
Harvoni's efficacy is undeniable. Depending on the genotype of the disease, functional cure rates ranged in the mid to high 90% range. Even more importantly, Harvoni finally casts aside the use of ribavirin and peg interferon for most patients, significantly reducing the number of side effects endured by those taking previous generation treatment regimens.
Since Sovaldi's efficacy warranted a high price, Gilead has similarly priced Harvoni at a premium. A 12-week course of treatment will set payers back $94,500.
That's a heady price that investors should take a moment to consider. According to Gilead, just 70,000 of the nearly 3 million people diagnosed with hepatitis C in the United States were treated with Sovaldi in the first two quarters; yet, Gilead's sales totaled in the billions. Because Harvoni is likely to displace Sovaldi as the go-to treatment, its higher price suggests Gilead's sales (and profit) will climb during the next 12 months -- that is, if payers agree to pay for it. Gilead's on the offensive to convince payers of the merits of Harvoni and its nearly six-figure price tag.
Alongside Gilead's price announcement, the company was quick to remind people that as many as 40% of hepatitis C patients may be able to achieve a functional cure in eight weeks rather than 12 weeks. The cost to treat those patients, who include those previously untreated without liver disease, would come in at just about $63,000, or 25% less than it would have cost to take Sovaldi.
The bigger picture
Gilead's Harvoni is a game-changing drug for the 120 million people diagnosed with the disease globally. It's pricing will likely incite scrutiny, but the company appears to have plenty of cover justifying it. A study conducted by the Henry Ford Health System in 2011, for example, found that the costs for caring for hepatitis C patients run an average of $24,175 per year. If so, even at this price, Harvoni appears a relative bargain.
Will Gilead be jealous of this coming blockbuster?
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you will need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Gilead Sciences, inc. Stock's Green Light Sparks Offensive originally appeared on Fool.com.Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Express Scripts, Gilead Sciences, and UnitedHealth Group. The Motley Fool owns shares of Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.